Immune Imprinting: The Persisting Influence of the First Antigenic Encounter with Rapidly Evolving Viruses

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2024 Aug 16

PMID 39149872

Authors

Mariam Maltseva

Alexa Keeshan

Curtis Cooper

Marc-Andre Langlois

Affiliations

Soon will be listed here.

Abstract

Immune imprinting is a phenomenon that stems from the fundamentals of immunological memory. Upon recurrent exposures to an evolving pathogen, the immune system must weigh the benefits of rapidly recalling established antibody repertoires with greater affinity to the initial variant or invest additional time and energy in producing responses specific to the emerging variant. In this review, we delve into the mechanistic complexities of immune imprinting and its role in shaping subsequent immune responses, both and recall, against rapidly evolving respiratory viruses such as influenza and coronaviruses. By exploring the duality of immune imprinting, we examine its potential to both enhance or hinder immune protection against disease, while emphasizing the role of host and viral factors. Finally, we explore how different vaccine platforms may affect immune imprinting and comment on vaccine strategies that can favor variant-specific antibody responses.

Citing Articles

Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever.

Sun D, Lien T, Chang H Int J Mol Sci. 2025; 26(5).

PMID: 40076527 PMC: 11899886. DOI: 10.3390/ijms26051898.

Antigenic Imprinting Dominates Humoral Responses to New Variants of SARS-CoV-2 in a Hamster Model of COVID-19.

Degryse J, Maas E, Lassauniere R, Geerts K, Kumpanenko Y, Weynand B Microorganisms. 2025; 12(12.

PMID: 39770793 PMC: 11678355. DOI: 10.3390/microorganisms12122591.

A polygeneric immunogen composed of 22 venoms from sub-Saharan African snakes to expand the neutralization scope of the EchiTAb-plus-ICP antivenom.

Sanchez A, Duran G, Cerdas M, Gutierrez J, Segura A, Herrera M Toxicon X. 2024; 24:100213.

PMID: 39640251 PMC: 11617979. DOI: 10.1016/j.toxcx.2024.100213.

Contribution of immunoglobulin products in influencing seasonal influenza infection and severity in antibody immune deficiency patients receiving immunoglobulin replacement therapy.

Ballow M, Ortiz-de-Lejarazu R, Quinti I, Miller M, Warnatz K Front Immunol. 2024; 15:1452106.

PMID: 39502688 PMC: 11534824. DOI: 10.3389/fimmu.2024.1452106.

References

Tan H, Juno J, Lee W, Barber-Axthelm I, Kelly H, Wragg K . Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nat Commun. 2021; 12(1):1403. PMC: 7930087. DOI: 10.1038/s41467-021-21665-8. View

Hassett K, Benenato K, Jacquinet E, Lee A, Woods A, Yuzhakov O . Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol Ther Nucleic Acids. 2019; 15:1-11. PMC: 6383180. DOI: 10.1016/j.omtn.2019.01.013. View

Burnett D, Jackson K, Langley D, Aggrawal A, Stella A, Johansen M . Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. Immunity. 2021; 54(12):2908-2921.e6. PMC: 8554075. DOI: 10.1016/j.immuni.2021.10.019. View

Johnston T, Li S, Painter M, Atkinson R, Douek N, Reeg D . Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity. 2024; 57(4):912-925.e4. DOI: 10.1016/j.immuni.2024.02.017. View

Liang F, Lindgren G, Lin A, Thompson E, Ols S, Rohss J . Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques. Mol Ther. 2017; 25(12):2635-2647. PMC: 5768558. DOI: 10.1016/j.ymthe.2017.08.006. View

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

Alsoussi W, Malladi S, Zhou J, Liu Z, Ying B, Kim W . SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature. 2023; 617(7961):592-598. DOI: 10.1038/s41586-023-06025-4. View

Schiepers A, Vant Wout M, Hobbs A, Mesin L, Victora G . Opposing effects of pre-existing antibody and memory T cell help on the dynamics of recall germinal centers. Immunity. 2024; 57(7):1618-1628.e4. PMC: 11236515. DOI: 10.1016/j.immuni.2024.05.009. View

Pierce S, Liu W . The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat Rev Immunol. 2010; 10(11):767-77. PMC: 3406597. DOI: 10.1038/nri2853. View

10.

Wang Q, Guo Y, Tam A, Valdez R, Gordon A, Liu L . Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell Rep Med. 2023; 4(11):101258. PMC: 10694617. DOI: 10.1016/j.xcrm.2023.101258. View

11.

Lewnard J, Cobey S . Immune History and Influenza Vaccine Effectiveness. Vaccines (Basel). 2018; 6(2). PMC: 6027411. DOI: 10.3390/vaccines6020028. View

12.

Simonsen L, Spreeuwenberg P, Lustig R, Taylor R, Fleming D, Kroneman M . Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. PLoS Med. 2013; 10(11):e1001558. PMC: 3841239. DOI: 10.1371/journal.pmed.1001558. View

13.

Cohen A, van Doremalen N, Greaney A, Andersen H, Sharma A, Starr T . Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science. 2022; 377(6606):eabq0839. PMC: 9273039. DOI: 10.1126/science.abq0839. View

14.

Ndifon W . A simple mechanistic explanation for original antigenic sin and its alleviation by adjuvants. J R Soc Interface. 2015; 12(112). PMC: 4685838. DOI: 10.1098/rsif.2015.0627. View

15.

Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M . Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine. N Engl J Med. 2023; 388(9):854-857. PMC: 9891359. DOI: 10.1056/NEJMc2214916. View

16.

Davis-Gardner M, Lai L, Wali B, Samaha H, Solis D, Lee M . Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022; 388(2):183-185. PMC: 9812288. DOI: 10.1056/NEJMc2214293. View

17.

Miller M, Gardner T, Krammer F, Aguado L, Tortorella D, Basler C . Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med. 2013; 5(198):198ra107. PMC: 4091683. DOI: 10.1126/scitranslmed.3006637. View

18.

Lindesmith L, Donaldson E, Leon J, Moe C, Frelinger J, Johnston R . Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol. 2009; 84(4):1800-15. PMC: 2812379. DOI: 10.1128/JVI.02179-09. View

19.

Ramsay L, Buchan S, Stirling R, Cowling B, Feng S, Kwong J . The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med. 2019; 17(1):9. PMC: 6327561. DOI: 10.1186/s12916-018-1239-8. View

20.

Gouma S, Anderson E, Hensley S . Challenges of Making Effective Influenza Vaccines. Annu Rev Virol. 2020; 7(1):495-512. PMC: 7529958. DOI: 10.1146/annurev-virology-010320-044746. View